VcMMAE

• UNSPSC Description:

  VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).

• Target Antigen:

  Drug-Linker Conjugates for ADC; Microtubule/Tubulin

• Type:

  ADC Related

• Related Pathways:

  Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage;Cytoskeleton

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/VcMMAE.html

• Solubility:

  DMSO : ≥ 54 mg/mL|Ethanol : 50 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(NC1=CC=C(COC(N(C)[C@@H](C(C)C)C(N[C@@H](C(C)C)C(N([C@@H]([C@@H](C)CC)[C@H](OC)CC(N2[C@@]([C@H](OC)[C@@H](C)C(N[C@H](C)[C@@H](O)C3=CC=CC=C3)=O)([H])CCC2)=O)C)=O)=O)=O)C=C1)=O)=O)NC(CCCCCN4C(C=CC4=O)=O)=O

• Molecular Weight:

  1316.63

• References & Citations:

  [1]Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897.|[2]Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75(7):1376-87.|[3]Jianmin Fang, et al. Anti-her2 antibody and conjugate thereof. US 20160304621 A1.

• Shipping Conditions:

  Blue Ice

• Clinical Information:

  No Development Reported

• CAS Number:

  646502-53-6